At the molecular level, ASTs inhibit activation of the TGF-β1/Smad2/3 pathway, thereby blocking EMT signaling and extracellular-matrix deposition, and consequently retarding pulmonary-fibrosis progression (106). The gene discussed is TGFB1; the disease is pulmonary fibrosis.